Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Richard S. Finn, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae-You Kim, Masatoshi Kudo, Ho Yeong Lim, Valeriy Vladimirovich Breder, Philippe Merle, Ahmed Omar Kaseb, Daneng Li, Yin-Hsun Feng, Wendy Verret, Derek-Zhen Xu, Sairy Hernandez, Beiying Ding, Andrew X. Zhu, Ann-Lii Cheng
Institutions: University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Nanjing General Hospital of Nanjing Military Command, National Cancer Center Hospital East, University Medical Center of the Johannes Gutenberg University Mainz, Institut Gustave Roussy, Seoul National University, Seoul National University Hospital, Kindai University Hospital, Kindai University, Samsung Medical Center, Sungkyunkwan University, Russian Cancer Research Center NN Blokhin, Ministry of Health of the Russian Federation, Hôpital de la Croix-Rousse, The University of Texas MD Anderson Cancer Center, City Of Hope National Medical Center, City of Hope, Beckman Research Institute, Chi Mei Medical Center, Genentech, Roche (China), Harvard University, Massachusetts General Hospital, National Taiwan University Hospital
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3032646207